Innocan receives LPT-CBD patent allowance in Japan

Executive Summary

• Innocan Pharma Corp.’s liposomal CBD injection technology (LPT‑CBD) patent has been allowed in Japan and will be granted pending final administrative steps.
• The Japanese patent adds to an existing international family, including a granted Indian patent, strengthening global IP protection for the company’s sustained‑release CBD formulation.
• The approval is highlighted as a key milestone supporting the advancement of LPT‑CBD toward FDA approval and commercialization in the world’s third‑largest pharmaceutical market (~$102 billion).

Key Details

• Patent covers a prolonged‑release liposome‑based formulation that encapsulates synthetic cannabidiol (CBD) for sustained bloodstream exposure.
• Japan is the third‑largest pharma market globally, valued at approximately US$102 billion.
• The allowed patent joins an existing granted Indian patent, expanding Innocan’s international IP portfolio.
• Development of LPT‑CBD was conducted jointly with Prof. Chezy Barenholz and Dr. Ahuva Cern (Hebrew University, Jerusalem).
• Preclinical studies show pharmacokinetics and pain‑relief effects lasting up to four weeks.
• Following a successful pre‑IND meeting, the U.S. FDA provided positive feedback on advancing LPT‑CBD toward approval as a non‑opioid chronic pain therapy.
• CEO Iris Bincovich emphasized that this is the second granted patent for LPT‑CBD and anticipates further approvals worldwide.
• Advisory board head Prof. Barenholz noted the allowance underscores the team’s innovation and positions LPT‑CBD as the first product advancing under this IP portfolio.
• Vice‑President of R&D Dr. Eyal Kalo highlighted a streamlined development plan toward FDA approval, citing pride in the patent milestone.

Notable Quotes

“We are thrilled to receive this patent allowance for our proprietary technology… This allowance marks our second patent to be granted for LPT‑CBD, further strengthening our innovation and global IP position.” – Iris Bincovich, CEO, Innocan Pharma

“The allowance of this patent provides strong evidence to the dedication and expertise of our development teams in driving innovation.” – Prof. Chezy Barenholz, Head of Advisory Board

“LPT‑CBD is progressing under a streamlined development plan toward FDA approval… we remain dedicated to advancing LPT‑CBD as a non‑opioid alternative for chronic pain management.” – Dr. Eyal Kalo, Vice‑President, R&D